A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China

A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China

Abstract Background Chronic graft-versus-host disease (cGVHD) is an immune-related disorder that is the most common complication post-allogenic hematopoietic stem cell transplant. Corticosteroids with or without calcineurin inhibitors (CNIs) remain the mainstay of cGVHD treatment for first-line ther...

Full description

Bibliographic Details
Main Authors: Ying Wang, Depei Wu, Xiang Zhang, Yuhua Li, Yanjie He, Qifa Liu, Li Xuan, Zhenyu Li, Kunming Qi, Yuqian Sun, Shunqing Wang, Wenjian Mo, Lei Gao, Ye Hua, Yu Wang, Ying Zhang
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Medicine
Subjects:
Belumosudil
cGVHD
ROCK2 inhibitor
ROCK
China
Efficacy
Online Access:https://doi.org/10.1186/s12916-024-03348-5

Internet

https://doi.org/10.1186/s12916-024-03348-5

Similar Items